VET PFAS Act
- Sponsor
- Rep. Lawler, Michael [R-NY-17]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Jun 6, 2025
Bottom line
The VET PFAS Act aims to provide comprehensive healthcare and disability benefits to military personnel and their families affected by PFAS contamination at U.S. military bases.
What it actually does
This bill expands eligibility for Department of Veterans Affairs (VA) hospital care and medical services to veterans and their family members who were exposed to per- and polyfluoroalkyl substances (PFAS) at military installations. It also establishes a presumption of service connection for certain diseases in exposed veterans, simplifying their access to disability compensation. The bill specifies conditions related to perfluorooctanoic acid (PFOA) and allows for future inclusion of other PFAS-related conditions based on ongoing scientific studies.
Proponents argue
Supporters argue that this bill addresses a critical public health issue for military families, providing long-overdue care and acknowledging the link between military service and exposure to harmful chemicals. They contend it streamlines access to vital benefits for those who have suffered health consequences due to their service environment.
Opponents contend
Critics may raise concerns about the potential for significant, unbudgeted costs associated with broadly expanding eligibility for healthcare and disability benefits. They might also argue that some conditions are included without sufficient scientific certainty of a direct causal link to PFAS exposure, potentially straining VA resources and setting a precedent for future expansions.
The bill is relatively short and its core provisions are clearly stated, making it accessible for an informed reader to evaluate within a reasonable timeframe.
Section 2(a), amending 38 U.S.C. 1710(e)(1)
VA Hospital Care and Medical Services for Exposed Veterans
This provision makes veterans who served at military installations contaminated with PFOA or other PFAS eligible for VA hospital care and medical services for specific diseases. These diseases include diagnosed high cholesterol, ulcerative colitis, thyroid disease, testicular cancer, kidney cancer, and pregnancy-induced hypertension for PFOA exposure. For other PFAS, eligibility extends to conditions the VA Secretary, in consultation with the Agency for Toxic Substances and Disease Registry (ATSDR), determines to have a positive association based on a 2018 study. Eligibility begins 90 days after enactment, even if there's insufficient medical evidence to directly attribute the illness to service.
Supporters argue
Supporters argue this provision ensures that veterans who were exposed to harmful chemicals while serving their country receive the necessary medical care, removing the burden of proving a direct causal link for conditions strongly associated with PFAS exposure.
Critics contend
Some may contend that broadening eligibility without absolute scientific certainty for every condition could lead to an unsustainable increase in demand for VA services and potentially divert resources from other critical veteran healthcare needs.
Tradeoffs
The provision balances the imperative to care for veterans potentially harmed by service-related exposures against the need for rigorous scientific evidence and the fiscal implications of expanding healthcare eligibility.
Section 2(b), adding 38 U.S.C. 1787A
VA Health Care for Family Members Exposed to PFAS
This section extends eligibility for VA hospital care and medical services to family members of exposed veterans. This includes individuals who resided at a covered military installation or were in utero while their mother resided there. They are eligible for care for the same conditions as veterans, starting 90 days after enactment. However, this care is subject to the availability of appropriations, cannot be furnished if the illness is found to result from another cause, and requires exhaustion of third-party claims (like health insurance) before VA reimbursement.
Section 3, adding 38 U.S.C. 1116C
Presumption of Service Connection for Exposed Veterans
This provision establishes a legal presumption that certain diseases or illnesses are service-connected for veterans who served at military installations contaminated with PFOA or other PFAS. The list of diseases is identical to those covered for hospital care (high cholesterol, ulcerative colitis, thyroid disease, testicular cancer, kidney cancer, and pregnancy-induced hypertension for PFOA, and other scientifically linked conditions for other PFAS). This presumption means veterans do not need to provide direct evidence linking their specific illness to their service, simplifying their claims for disability compensation. Service by reservists at covered installations is also treated as active duty for this purpose.
Section 2(c)
Annual Reporting Requirement on Care and Services
This section mandates that the Secretary of Veterans Affairs submit annual reports to Congress for a three-year period, starting after the study conducted under section 316 of the FY2018 NDAA is submitted. These reports must detail the number of veterans and family members who received care and services under the new provisions, the specific illnesses and conditions treated, the number of denied applications (with reasons), and the number of pending applications.
The bill defers to a future determination by the Secretary of Veterans Affairs, in consultation with the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR), based on the study conducted under section 316 of the National Defense Authorization Act for Fiscal Year 2018 (Public Law 115-91), to define additional PFAS-related diseases, illnesses, or conditions eligible for hospital care, medical services, and presumption of service connection.
Section 2(a)(1)(J)(ii)(II) and Section 3(b)(2)
Why it matters:This is standard legislative practice to allow for scientific updates and administrative flexibility. It enables the scope of covered conditions to evolve as new scientific findings emerge regarding the health impacts of various PFAS, without requiring new legislation for each update.
Case for: Supporters argue that this mechanism ensures the bill remains responsive to evolving scientific understanding, allowing for the inclusion of newly identified PFAS-related conditions without legislative delays, thereby providing timely care and benefits to affected individuals.
Case against: Critics might contend that this approach introduces uncertainty regarding the full scope and ultimate cost of the bill, as the specific conditions covered beyond PFOA are not explicitly defined at the time of enactment. This could lead to delays in access to care for conditions not yet formally recognized.
Estimated impact: This provision significantly impacts the long-term scope and cost of the bill, as it allows for the expansion of covered conditions based on ongoing scientific research, potentially increasing the number of eligible veterans and family members and the associated federal expenditures.